We studied in vitro metabolism of rapamycin using pig liver microsomes. After extraction of the metabolites from the incubation medium, the crude metabolite extract was submitted to normal and subsequently to reversed-phase HPLC chromatography. We describe in the current study a metabolite of retention time 23.2 min collected from reversed-phase HPLC and identified by fast atom bombardment mass spectrometry (MS) and electrospray MS-MS as a C 39 demethylated rapamycin metabolite. In vitro immunosuppressive activity of this metabolite, determined by the mixed lymphocyte reaction, was negligible compared with that of the parent compound. The decrease of in vitro immunosuppressive activity compared with the parent compound is likely to be attributed to important structural modifications of the rapamycin binding region to the FK-506 binding protein.
We studied in vitro metabolism of rapamycin using pig liver microsomes. After extraction of the metabolites from the incubation medium, the crude metabolite extract was submitted to normal and subsequently to reversed-phase HPLC chromatography. We describe in the current study a metabolite of retention time 23.2 min collected from reversed-phase HPLC and identified by fast atom bombardment mass spectrometry (MS) and electrospray MS-MS as a C 39 demethylated rapamycin metabolite. In vitro immunosuppressive activity of this metabolite, determined by the mixed lymphocyte reaction, was negligible compared with that of the parent compound. The decrease of in vitro immunosuppressive activity compared with the parent compound is likely to be attributed to important structural modifications of the rapamycin binding region to the FK-506 binding protein.
Rapamycin (sirolimus, AY-22,989, C 51 H 79 NO 13 ), isolated from a strain of Streptomyces hygroscopus [1] , is a 31membered macrolide lactone with a molecular mass of 913.6 Da. Although rapamycin was originally developed as an antifungal and antitumor drug, the focus of current interest has shifted towards its immunosuppressive properties [2] . Rapamycin binds to the same intracellular binding protein in lymphocytes (FKBP or FK-506 binding protein) as its structural homolog, the immunosup-pressive drug FK-506 [3] , and inhibits the S6p70-kinase [4] , an immunosuppressive mechanism of drug biological action quite different from that of FK-506 (tacrolimus), which inhibits the phosphatase activity of calcineurin in vitro [5] . 3 The cytochrome P-450 3A-dependent mixed-function oxygenase system is responsible for the metabolism of rapamycin [6] . Some hydroxylated and (or) demethylated metabolites of rapamycin were isolated and identified from human liver microsomes and rat small intestinal microsomes, among them the 41-O-demethyl rapamycin metabolite [7] , also called 39-O-demethyl rapamycin, following the numbering of atoms of the Cambridge Structure Data Bank [8] .
We describe in this study the isolation of the 39-Odemethyl rapamycin metabolite from pig liver microsomes and the structural identification of this compound by fast atom bombardment (FAB) and electrospray tandem mass spectrometry (MS-MS). We also discuss the results of in vitro immunosuppressive activity of this metabolite in terms of structure-activity relation using the mixed lymphocyte reaction (MLR).
Materials and Methods
Chemicals and reagents. Rapamycin (white powder, batch AY-22989 -21) was graciously supplied by Wyeth-Ayerst Research. "Spectrograde" solvents (acetonitrile, dichloromethane, and isopropanol) used in extraction or analytical procedures were purchased from Labscan Unit T26 and hexane from Alltech Associates, Applied Science Labs. NADP ϩ , glucose-6 phosphate, and glucose-6-phosphate dehydrogenase grade II (5 g/L) were purchased from Boehringer Mannheim. The matrix used in FAB/MS, 3-nitrobenzyl alcohol, was manufactured by Aldrich-Chemie. Demineralized and filtered (MilliQ water purification system; Millipore-Waters) water was used. All cell culture reagents were obtained from Gibco Labs.
Animals. Female Landrace Belgium pigs (ϳ16 kg) were maintained in individual cages and were given free access to commercial food pellets (Versele-Laga) and water.
Preparation of pig liver microsomes. After intracardiac injection of 20 mmol of a KCl solution (1 mol/L), the liver was removed, weighed, cut into seven pieces of ϳ100 g, and stored in a refrigerator at Ϫ80°C. The pieces of liver were removed, weighed, washed with ice-cold 3 mmol/L imidazole homogenizing medium containing 0.5 mol/L sucrose, minced with scissors, and fractionated according to a described method [9] to produce a microsomal fraction containing 4.62 g/L protein and 0.43 nmol of cytochrome P-450/mg protein determined according to published standard procedures [10, 11] .
Rapamycin microsomal incubation medium and extraction of the metabolites. To the NADPH-generating medium (1.6 mL) containing 5.08 mg of NADP ϩ , 0.4 mL of MgCl 2 (0.5 mol/L), 10 mg of glucose-6 phosphate, and 1.2 mL of Tris (pH 7.4) were added 5 mL of pig liver microsomes, 1.2 L of glucose-6-phosphate dehydrogenase (specific activity 350 kU/g), and 5 g of rapamycin/mg protein dissolved in acetonitrile (1 g/L), in a total volume of 6.6 mL. This mixture was incubated for 1 h at 37°C in 50-mL Erlenmeyer flasks and transferred to a centrifuge tube. Fourteen milliliters of dichloromethane were added, vortexmixed for 2 min, and centrifuged for 20 min at 3800g. The aqueous phase was discarded and the residue remaining after evaporation of the organic phase under reduced pressure was dissolved in 800 L of isopropanol. The resulting solution was then submitted to HPLC analysis.
HPLC. The HPLC system consisted of a HP 1090 HPLC system (Hewlett-Packard) connected to a Diode-Array detector HP 1050. Rapamycin metabolites were first separated in normal phase on an Alltech Rsil column (10 mm, length 250 mm, i.d. 10 mm) fitted with a Lichrosorb CN precolumn (Merck) with a gradient of hexane (from 100 Clinical Chemistry 44, No. 3, 1998 mL/L to 600 mL/L):isopropanol (from 900 mL/L to 400 mL/L) during 35 min, followed by an isocratic hexane: isopropanol (60:40) phase as the mobile phase. Flow rate and UV detector settings were 2 mL/min and 276 nm, respectively. Groups of peaks with retention times (RT) 27 to 55 min were then collected and after evaporation of the mobile phase the residue was dissolved in acetonitrile. The resulting solution was then rechromatographed on a reversed-phase HPLC system consisting of three columns in tandem (Nova-Pak-C 18 4 m, Waters, 3.9 ϫ 150 mm Nucleosil-C 18 ,, 5 m, 4 ϫ 250 mm, Macherey-Nagel, and Supelco, LC-18 DB, 5 m, 4.6 ϫ 250 mm, Sercolab) at 40°C by using a gradient of acetonitrile (from 480 mL/L to 1000 mL/L):water (from 520 mL/L to 0 mL/L) as the mobile phase. Flow rate and UV detector settings were 1 mL/min and 276 nm, respectively. Under these conditions, the major peaks were detected and collected. After evaporation of the mobile phase under reduced pressure, the residues were dissolved in acetonitrile, transferred to individual tubes, preweighed on a semimicro balance (Precisia), and evaporated to dryness under a stream of nitrogen.
FAB/MS. FAB mass spectra were obtained with a Kratos (Kratos Analytical) MS80 RFA instrument. Metabolites (100 g) were dissolved in dichloromethane. Small aliquots of the resulting solution were slowly transferred and evaporated on a copper probe tip (standard Kratos FAB probe) before adding a fixed amount (6 mg) of a 3-nitrobenzyl alcohol matrix. Xenon gas was used in the Kratos FAB source with a primary energy of 7.8 kV.
Electrospray MS-MS. Electrospray MS-MS spectra were obtained with a Finnigan Mat LCQ and MS n instrument. The source voltage was 5.05 kV, the capillary voltage 25.76 V, and the capillary temperature 220.10°C. The compounds (100 g) were dissolved in a mixture of acetonitrile:5 mmol/L aqueous solution of ammonium acetate (50:50) and the solution was infused with the aid of a syringe pump at a flow rate of 5 L/min.
Functional assays to determine the immunosuppressive effect.
Mononuclear cells were isolated from human peripheral blood by density gradient centrifugation on Ficoll-Hypaque medium (International Medical, d ϭ 1.077). After washing, the cells were suspended in enriched RPMI medium at a concentration of 2 ϫ 10 9 cells/L [12] . The enriched RPMI medium consisted of 770 mL/L RPMI medium 1640 (Gibco), 200 mL/L fetal calf serum (Biosys), 10 mL/L glutamine, 10 mL/L penistreptomycin (5000 kU/L), and 10 mL/L gentamicin (50 g/L). In microplates, 10 5 cells/well (50 L) were incubated at 37°C and 5% CO 2 for 5 days with 50 L of the metabolite solution, GBq (0.2 Ci)/L, Isotopchim]. Cell cultures were harvested with an automated multiwell harvester (Skatron) that first aspirates cells, lyses them, and transfers their DNA onto filter paper, while allowing unincorporated [ 3 H]thymidine to wash out. The incorporation was determined by liquid scintillation counting (beta counter cpm, Beckman LS 6000SE) after an additional 8-h incubation. The potential inhibitory response of each solution was calculated in cpm and expressed as the percentage of inhibition of a normal response (MLR performed in absence of any solution). Each culture, including positive and negative controls, was performed in triplicate, and then repeated five times. Pure rapamycin and solvent additions were the positive and negative controls, respectively.
Results and Discussion
The reversed-phase chromatogram resulting from the incubation of rapamycin in the presence of pig liver microsomes is illustrated in Fig. 1 and reveals the presence of metabolic peaks of RTs 8.5 min, 11.2 min, 18.6 min, and 23.2 min. The remaining chromatographic peaks observed at 25.9 min, 26.7 min, and 27.8 min are tautomers of unchanged rapamycin as confirmed by FAB/ MS. The metabolite at RT 11.2 is a 5,6-dihydrodiol metabolite already identified from rat liver microsomes [13] .
The FAB mass spectrum of the metabolite at RT 23.2 (Fig. 2) Fig. 3 . Because ring-chain tautomerism effects exist between the lactone function and the corresponding carboxylic acid with the formation of a double bond at the C 25 -C 26 positions, a fragmentation process in the ␣ position of the double bond is observed giving rise to a fragment ion of mass m/z ϭ 785, demonstrating that demethylation occurred at the rapamycin C 39 position. Also, the fact that fragment ions are observed resulting in the elimination of pipecolic acid indicates that some intramolecular interactions between the C 39 hydroxy group and the C 16 carbonyl are possible, giving rise to a carbinolamine intermediate that is able to lose pipecolic acid, as already observed for tacrolimus [14, 15] .
These observations were confirmed by electrospray MS (Fig. 4) and MS-MS measurements on this rapamycin metabolite characterized mainly by the presence of quasimolecular ions of mass m/z ϭ 917 (M ϩ NH 4 ) ϩ , 922 (M ϩ Na) ϩ , and 938 (M ϩ K) ϩ , confirming that rapamycin was submitted to a phase I demethylation reaction. When the sodium adduct (m/z ϭ 922) was selected as the parent ion, daughter ions of mass m/z ϭ 890 (M Ϫ CH 3 OH)Na ϩ , 872 (M Ϫ CH 3 OH Ϫ H 2 O)Na ϩ , 614 (M Ϫ 308)Na ϩ, 582 (M Ϫ 308 Ϫ CH 3 OH)Na ϩ , and 564 (M Ϫ 308 Ϫ CH 3 OH Ϫ H 2 O)Na ϩ were observed, as shown in the Fig. 5 , confirming again that demethylation occurred at the rapamycin C 39 position. The daughters of the parent ion m/z ϭ 890 were found to be 872 (890 Ϫ H 2 O) ϩ , 779 (890 Ϫ 111) ϩ , 761(890 Ϫ pipecolic acid) ϩ , 735(890 Ϫ 111 Ϫ CO 2 ) ϩ , 717(890 Ϫ 111 Ϫ CO 2 Ϫ H 2 O) ϩ , 582(890 Ϫ 308) ϩ , and 564 (890 Ϫ 308 Ϫ H 2 O) ϩ (data not shown). The fact that pipecolic acid or 2-formyl piperidine 2-ene, as also observed for tacrolimus metabolites [14] , may be lost from the parent ion m/z ϭ 890 confirms that intramolecular interactions of free hydroxy groups with the C 16 rapamycin carbonyl function are possible to produce a carbinolamine intermediate.
The in vitro immunosuppressive activity of MLR by the C 39 demethylated rapamycin metabolite is essentially zero until 25 g/L (Fig. 6 ). The 50% immunosuppressive concentration (IC 50 ) of rapamycin is 2 ϫ 10 Ϫ4 g/L (data not shown) and of the C 39 demethylated metabolite 2 ϫ 10 2 g/L, which is 10 Ϫ6 times lower than that of rapamycin. In the higher concentration range, the immunosuppressive activity increases progressively from 25 to 1000 g/L, where the last recorded value is similar to the one of rapamycin. These results are in agreement with the ones obtained recently for four rapamycin metabolites isolated from urine of renal transplant recipients, since the observed immunosuppressive activities in MLR [16] were small at a concentration of 40 g. Probably the 39-Odemethyl metabolite was present among these four metabolites. The metabolite obtained from pig liver was estimated to be 5% of unchanged rapamycin (comparison between the surfaces under the curve in the HPLC chromatogram). The same metabolite was already isolated from human liver microsomes [7] and inhibited phytohemagglutinin-induced lymphocyte proliferation. The amount and the immunosuppressive activity of this metabolite are both low, leading to a negligible contamination in current therapeutic monitoring methods of rapamycin. Kessler et al. reported [17] that the binding region, including the C 11 to C 23 and C 37 to C 44 positions of rapamycin, is nearly identical to the one of tacrolimus. Intramolecular interactions of free hydroxy groups at the rapamycin C 16 position to produce a carbinolamine intermediate were observed in FAB as well as in electrospray MS. Also, intermolecular interactions with FKBP-12 may give rise to the formation of several tautomeric forms of the C 39 demethylated rapamycin metabolite, presenting different binding affinities for FKBP-12. The decrease of in vitro immunosuppressive activity is likely to be attributed to important structural modifications of the rapamycin binding region to FKBP-12, including intramolecular interactions of the C 39 hydroxy group with the lactone function, producing another ring tautomer very similar to the one described for iso-FK-506 [18, 19] and decreasing the binding affinity of this rapamycin metabolite for its pharmacological receptor FKBP-12.
We conclude that rapamycin is metabolized in vitro under the influence of cytochrome P-450-dependent mixedfunction oxygenase enzymic system to a C 39 demethylated rapamycin metabolite characterized by an in vitro immunosuppressive activity that is essentially zero.
